Pharmaceutical company Merck is planning to separate its human health business into two divisions, according to a Monday report from The Wall Street Journal. The move is intended to alleviate operational pressure resulting from the patent expiration of its top-selling drug, Keytruda.

One division will focus on cancer drugs, including Keytruda, while the other will handle the sales of non-cancer medications.